Table 1. Patients' characteristics: 140 patients with G1-G2-G3 NET treated with somatostatin analogues.
| Parameters | n° of patients (%) | |
|---|---|---|
| Age | mean±SE, range | 59±2.6 (21-86) |
| Gender M/F | 74 / 66 | |
| Site of primary tumour | Lung | 26 (19) |
| Thymus | 5 (4) | |
| Stomach | 8 (6) | |
| Pancreas | 60 (44) | |
| Ileum | 18 (12) | |
| Other sites* | 7 (3) | |
| Unknown primary | 16 (12) | |
| Biology | Sporadic | 123 (88) |
| MEN1 | 17 (12) | |
| Grading | G1 | 49 (35) |
| G2 | 61 (44) | |
| G3 | 30 (21) | |
| Stage | Loco-regional disease | 62 (45) |
| Distant metastases | 78 (55) | |
| Nonfunctioning tumour | 119 (85) | |
| Functioning tumour | Zollinger-Ellison syndrome | 6 (4.3) |
| Hypoglicemic syndrome | 5 (3.6) | |
| Carcinoid syndrome | 10 (7.1) | |
| Positive circulating NE markers | Serum Chromogranin-A | 66 (47) |
| Serum Gastrin | 11 (7.8) | |
| Serum Insulin/C-peptide | 5 (3.6) | |
| 24-h-urinary 5-HIAA | 10 (7.1) | |
| Octreoscan | Positive | 46 (75) |
| Negative | 15 (25) | |
| 68Ga-DOTATATE -PET | Positive | 29 (83) |
| Negative | 6 (17) |
NET: neuroendocrine tumour; NE: neuroendocrine; 5-HIAA: 5-hydroxyindolacetic acid; *colon-rectum, duodenum, appendix.